Tags

Type your tag names separated by a space and hit enter

Long-term management of insulin-treated diabetic patients with continuous subcutaneous insulin infusion.
Diabete Metab. 1983 Mar; 9(1):45-52.DM

Abstract

Ten ambulatory diabetics were submitted to continuous subcutaneous insulin infusion (CSII) for periods of 6-18 months. With the exception of a patient who demonstrated a subcutaneous abscess, local tolerance was good. One patient suffered a severe hypoglycemic attack during the first days of CSII. Among the other subjects, hypoglycemic reactions were rare. However, blood glucose values under 50 mg/dl were recorded as frequently as during the control period. There was a non significant increment in insulin requirements and weight increased in almost all patients. In comparison with prepump period, we observed at the end of the study a significant decrease of mean blood glucose (140 vs 203 mg %), of urinary glucose output (8 vs 21 g/24 hr) and of HbA1 levels (7.6 vs 9.6%). As a rule, the improvement of diabetes control was noted throughout the study period. Nevertheless, normoglycemia was rarely reached. Diabetes stability improved as evidenced by a decrease of the standard deviation of monthly blood glucose values and by a reduction of M and MAGE indexes. In spite of the better metabolic control, we did not observe an improvement of renal function while lipid values were slightly modified. Motor nerve conduction velocities increased in 6 patients and ocular fluoroangiographic records demonstrated a reduction of microaneurysms and/or microhemorrhagic dots. As a group, the patients were satisfied with CSII and 8 of them wished to continue indefinitely with this treatment.

Authors

Daubresse JC
No affiliation info available
Henrivaux P
No affiliation info available
Bailly A
No affiliation info available
Lemy C
No affiliation info available
Duchateau A
No affiliation info available

MeSH

AdultAlbuminuriaAttitudeBlood GlucoseDiabetes MellitusDiabetic NeuropathiesDiabetic RetinopathyElectromyographyGlycated Hemoglobin AHumansInsulin Infusion SystemsMiddle Aged

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

6852337

Citation

Daubresse, J C., et al. "Long-term Management of Insulin-treated Diabetic Patients With Continuous Subcutaneous Insulin Infusion." Diabete & Metabolisme, vol. 9, no. 1, 1983, pp. 45-52.
Daubresse JC, Henrivaux P, Bailly A, et al. Long-term management of insulin-treated diabetic patients with continuous subcutaneous insulin infusion. Diabete Metab. 1983;9(1):45-52.
Daubresse, J. C., Henrivaux, P., Bailly, A., Lemy, C., & Duchateau, A. (1983). Long-term management of insulin-treated diabetic patients with continuous subcutaneous insulin infusion. Diabete & Metabolisme, 9(1), 45-52.
Daubresse JC, et al. Long-term Management of Insulin-treated Diabetic Patients With Continuous Subcutaneous Insulin Infusion. Diabete Metab. 1983;9(1):45-52. PubMed PMID: 6852337.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term management of insulin-treated diabetic patients with continuous subcutaneous insulin infusion. AU - Daubresse,J C, AU - Henrivaux,P, AU - Bailly,A, AU - Lemy,C, AU - Duchateau,A, PY - 1983/3/1/pubmed PY - 2000/3/11/medline PY - 1983/3/1/entrez SP - 45 EP - 52 JF - Diabete & metabolisme JO - Diabete Metab VL - 9 IS - 1 N2 - Ten ambulatory diabetics were submitted to continuous subcutaneous insulin infusion (CSII) for periods of 6-18 months. With the exception of a patient who demonstrated a subcutaneous abscess, local tolerance was good. One patient suffered a severe hypoglycemic attack during the first days of CSII. Among the other subjects, hypoglycemic reactions were rare. However, blood glucose values under 50 mg/dl were recorded as frequently as during the control period. There was a non significant increment in insulin requirements and weight increased in almost all patients. In comparison with prepump period, we observed at the end of the study a significant decrease of mean blood glucose (140 vs 203 mg %), of urinary glucose output (8 vs 21 g/24 hr) and of HbA1 levels (7.6 vs 9.6%). As a rule, the improvement of diabetes control was noted throughout the study period. Nevertheless, normoglycemia was rarely reached. Diabetes stability improved as evidenced by a decrease of the standard deviation of monthly blood glucose values and by a reduction of M and MAGE indexes. In spite of the better metabolic control, we did not observe an improvement of renal function while lipid values were slightly modified. Motor nerve conduction velocities increased in 6 patients and ocular fluoroangiographic records demonstrated a reduction of microaneurysms and/or microhemorrhagic dots. As a group, the patients were satisfied with CSII and 8 of them wished to continue indefinitely with this treatment. SN - 0338-1684 UR - https://www.unboundmedicine.com/medline/citation/6852337/Long_term_management_of_insulin_treated_diabetic_patients_with_continuous_subcutaneous_insulin_infusion_ L2 - https://medlineplus.gov/diabetes.html DB - PRIME DP - Unbound Medicine ER -